# Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF

> **NCT02846324** · PHASE2 · COMPLETED · sponsor: **Global Blood Therapeutics** · enrollment: 39 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis
- Hypoxemia

## Interventions

- **DRUG:** GBT440
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02846324
- **Lead sponsor:** Global Blood Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2017-09
- **Final completion:** 2017-11
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2020-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02846324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02846324, "Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02846324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*